Spark has submitted updated Phase I/II choroideremia data for ARVO meeting in April; earlier-stage patients show improved albeit nonstatistically significant efficacy, exec says

08 Jan 2019

Spark has submitted updated Phase I/II choroideremia data for ARVO meeting in April; earlier-stage patients show improved albeit nonstatistically significant efficacy, exec says

Spark Therapeutics (NASDAQ:ONCE) has submitted interim Phase I/II data for its choroideremia drug, SPK-7001, to the Association for Research in Vision and Ophthalmology (ARVO) for its conference in April, said Katherine High, president and head of R&D, on the sidelines of the ongoing J.P. Morgan Healthcare Conference in San Francisco. Data from recently enrolled patients in the gene therapy study, which started in January 2015, showed some benefit but did not demonstrate statistically significant efficacy, she noted.

Already a subscriber? Login to read the full article.

 
1 Start 2 Complete